Systemic Therapies for HER2-Positive Advanced Breast Cancer
Despite recent advances, HER2-positive advanced breast cancer (ABC) remains a largely incurable disease, with resistance to conventional anti-HER2 drugs ultimately unavoidable for all but a small minority of patients who achieve an enduring remission and possibly cure. Over the past two decades, sig...
Main Authors: | Vasileios Angelis, Alicia F. C. Okines |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/16/1/23 |
Similar Items
-
HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks
by: Mandó P, et al.
Published: (2023-02-01) -
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
by: Ilana Schlam, et al.
Published: (2022-08-01) -
Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
by: Yu Y, et al.
Published: (2022-12-01) -
Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
by: Matti Aapro, et al.
Published: (2022-12-01) -
The History and Development of HER2 Inhibitors
by: Xiaohui Xia, et al.
Published: (2023-10-01)